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Context: Conventional management of hypoparathyroidism has focused upon maintaining the
serum calcium with oral calcium and active vitamin D, often requiring high doses and giving rise
to concerns about long-term consequences including renal and brain calcifications. Replacement
therapywith PTH has recently become available. This paper summarizes the results of the findings
and recommendations of the Working Group on Management of Hypoparathyroidism.
Evidence acquisition: Contributing authors reviewed the literature regarding physiology, patho-
physiology and nutritional aspects of hypoparathyroidism, management of acute hypocalcemia,
clinical aspects of chronicmanagement, and replacement therapyofhypoparathyroidismwithPTH
peptides. PubMed and other literature search engines were utilized.
Evidence synthesis: Under normal circumstances, interactions between PTH and active vitamin D
along with the dynamics of calcium and phosphorus absorption, renal tubular handing of those
ions, and skeletal responsiveness help to maintain calcium homeostasis and skeletal health. In the
absence of PTH, the gastrointestinal tract, kidneys, and skeleton are all affected leading to hy-
pocalcemia, hyperphosphatemia, reduced bone remodeling, and an inability to conserve filtered
calcium. Acute hypocalcemia can be a medical emergency presenting with neuromuscular irrita-
bility. The recent availability of human recombinant PTH(1–84) has given hope that management
of hypoparathyroidism with the missing hormone in this disorder will provide better control and
reduced needs for calcium and vitamin D.
Conclusions: Hypoparathyroidism is associated with abnormal calcium and skeletal homeostasis.
Control with calcium and active vitamin D can be a challenge. The availability of PTH(1–84) re-
placement therapymayusher newopportunities for better controlwith reduced supplementation
requirements.
Physiology, pathophysiology and nutritional aspects of hypoparathyroidism
To protect the organism against overload or deficiencyof calcium, phosphate and other ions, homeostasis is
aimed at maintaining extracellular concentrations as con-
stant and minimally variant as possible (1). It is particu-
larly important to maintain extracellular calcium concen-
tration as stable as possible, because of the high sensitivity
of a variety of cell systems or organs, including the central
nervous system (CNS), muscle, and exo-/endocrine
glands, to small variations in this divalent cation. Extra-
cellular calcium is maintained within a narrow range by
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bidirectional calcium fluxes taking place at the level of the
intestine, bone and kidney. In the absence of parathyroid
hormone or in states of resistance to its action, however,
extracellular calcium concentration ismuchmore likely to
fall since homeostatic mechanisms in all three target or-
gans are impaired.
Intestinal calcium absorption
Under normal conditions, intestinal absorption of cal-
cium represents approximately 20%-30%of ingested cal-
cium (2, 3). The latter could be decreased in pathological
conditions such as celiac disease, in which net calcium
absorption is reduced. Except in the elderly with achlo-
rhydria, in whom calcium carbonate absorption may be
impaired (4), the different forms of calcium including
dairy products are similarly absorbed (5). Dairy products
are an important dietary source of calciumbecause of their
high calcium content and absorbability (6). They provide
more calcium, protein, magnesium, potassium, zinc and
phosphorus per calorie than any other usual food found in
the adult diet (7). Furthermore, dairy products are rich in
aromatic aminoacids,which stimulatehepatic production
of IGF-1 (8). Intestinal absorption of calcium is enhanced
by IGF-1 by virtue of its effect to stimulate renal calcitriol.
When ingested during a protein-containing meal, calcium
is better absorbed with less variability (9). Recommended
dietary allowance for protein is 0.8 g/kg body weight.
However, in older people, it appears that higher intakes
are necessary, approximately 1.1–1.2 g/kg body weight.
Intestinal calcium absorptive capacity is mainly con-
trolled by calcitriol, which stimulates calcium transport
through both genomic and nongenomic mechanisms (2).
The normal daily production rate of calcitriol is 0.5–1
mcg/d (10). In hypoparathyroidism, the lack of PTH is
associated with lower calcitriol levels, hence reduced in-
testinal absorption of calcium.The hyperphosphatemia of
hypoparathyroidism also limits the production of cal-
citriol. Under these conditions, plasma calcium homeo-
stasis is dependent on higher intestinal cation influx. In-
creasing dietary intake of calcium, calcium supplements
and active vitamin Dmetabolites can all facilitate calcium
absorption. To avoid substantial increases in postprandial
urinary calcium excretion, calcium intake should be
evenly distributed during the day. In many instances, in-
creasing the amount of calcitriol can reduce the amount of
supplemental calcium required.
Prebiotics such as galacto-oligosaccharides are fer-
mented by microflora in the large intestine, lowering pH
and thereby enhancing calcium absorption (11). The large
intestine contains a potent vitamin D-dependent calcium
transport system, which under normal conditions, con-
tributes little to calciumhomeostasis, since calcium reach-
ing the large intestine is complexed to various anions and
is thereby poorly bioavailable.
When hypocalcemia occurs and its etiology is not
known, magnesium deficiency should be suspected (12).
Magnesium deficiency is associated with impaired secre-
tion and action of PTH. Magnesium is present in all nu-
trients from cellular origin. Dietary sources of magnesium
include almonds, soybean, seeds,wheat germ,wheat bran,
millet, dark green vegetables, fruit, and seafood. Recom-
mended daily allowance of magnesium is 420 and 320
mg/d for men and women, respectively. Dietary inade-
quacy of magnesium is most unusual under normal cir-
cumstances. But if magnesium is being persistently lost
from the intestine or kidney, dietary intake may become
insufficient. Net intestinal absorption of magnesium is
proportional to intake, but usually averages 35 to 40%.
Phosphate and cellulose phosphate form a complex with
magnesium, thereby impairing its absorption. A lowpH is
important to displace magnesium bound to dietary fibers
and to make it available to absorptive processes. Thus,
prolonged nasogastric suction or chronic diarrhea, par-
ticularly when due to laxative abuse, are risk factors for
magnesium depletion. Upper gastrointestinal (GI) tract
fluid contains 2 mmol/L of magnesium whereas in diar-
rheal fluidmagnesium concentrationmay be as high as 30
mmol/L.
Role of the kidney
PTH increases renal tubular calcium reabsorption. In
chronic hypoparathyroidism, relative renal calcium clear-
ance is higher than normal despite reduced glomerular
filtration of calcium. There is some correlation between
the renal clearances of calcium and sodium. High sodium
intakes may be associated with hypercalciuria. A sound
measure in the management of patients with hypopara-
thyroidism is to limit sodium intake, a step that may re-
duce hypercalciuria. Loop diuretics increase urinary cal-
cium excretion and are contraindicated in patients with
hypoparathyroidism.
Role of bone resorption
About 1% of total bone calcium exchanges every
month, through bidirectional fluxes, under the influence
of parathyroid hormone and/or calcitriol. Besides calcitri-
ol’smain action to enhance dietary calciumabsorption, an
additional effect is to stimulate bone resorption, shown
best in animal models (13). In the absence of parathyroid
hormone, calcium efflux from bone is more dependent
upon calcitriol. A large variety of substances either circu-
lating or produced locally, or present in the bone matrix,
are also capable of influencing these fluxes (1), but they are
not available pharmacologically. Many nutrients have
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been shown, primarily in animal studies, to influence bone
resorption, such as dried plum, blueberries, fish oil, zinc,
grapes and the phyto-estrogen genistein (14–19). How-
ever, these nutrients appear to reduce bone turnover, in-
steadof stimulating bone resorption, and cannot therefore
be considered useful as therapeutic adjuncts in
hypoparathyroidism.
Management of acute hypocalcemia
In hypoparathyroidism, hypocalcemia can occur
acutely and become a true medical emergency. Hypocal-
cemia is defined as an ionized serum calcium (Ca2) con-
centration that falls below the lower limit of the normal
range. Approximately 50% of the total serum Ca is in the
ionized fraction, with the remainder being protein-bound
(predominantly to albumin) or complexed to anions such
as phosphate. Estimation of the corrected serum total Ca
can be obtained with the following formula: corrected
serum total Ca  measured total Ca  [0.8 x (4.0-mea-
sured serum albumin)]. In assessing the degree of hypocal-
cemia, the corrected serum calcium should be used. In
settings where an accurate, direct ionized serum calcium
can be obtained, this measurement can also be useful in
guiding the acute therapeutic approach. Several recent re-
views present detailed information on this topic (20–24).
The treatment of hypocalcemia in hypoparathyroidism
is influenced not only by the actual calcium concentration
but also by any associated symptoms. In hypoparathy-
roidism, many subjects chronically demonstrate calcium
levels in the low normal or mild hypocalcemic range. The
symptoms of hypocalcemia do not always follow strictly
the extent to which the calcium is low. The severity of
symptoms (paresthesias, carpal- pedal spasm, broncho- or
laryngospasm, tetany, seizures or mental status changes)
and signs (Chvostek’s or Trousseau’s signs, bradycardia,
impaired cardiac contractility and prolongation of theQT
interval) all depends upon the absolute level of calcium,
the rate of decrease, and individual variability. No two
subjects appear to be alike in these respects. Some patients
with marked hypocalcemia will appear to be asymptom-
atic while others with what appears to be mild hypocal-
cemia may be symptomatic.
Clinical features of hypocalcemia for which intrave-
nous (IV) calciumadministration shouldbe consideredare
indicated above. In addition, even though some patients
with marked hypocalcemia [ie, corrected calcium  7.0
mg/dL (1.75mmol/L)]maynotbe symptomatic, IV ther-
apy may be indicated because at those levels, life-threat-
ening features can appear rather suddenly such as laryn-
geal spasm and seizures. Patients who become unable to
take or absorb oral supplements can become quickly
symptomatic even though the serumcalciummaynothave
fallen dramatically at the time they present with symp-
toms. Finally, there are some women who typically be-
come symptomatic during the luteal phase of their men-
strual cycle. In these situations, clinical judgment and
prompt decision making to opt for IV calcium are
required.
When clinical circumstances dictate urgent treatment,
IVCa2 salts are used. The goals of IV calcium therapy are
to control symptoms, reverse signs (eg, prolonged QT in-
terval), and to restore the serum calcium level to the lower
end of the normal range. Initially, IV calcium (1 to 2 g of
calcium gluconate, equivalent to 90–180 mg elemental
calcium, in 50mL of 5% dextrose) can be infused over 10
to 20 minutes. As is true for the IV administration of any
electrolyte solution, calciumshouldnotbegivenmore rap-
idly because of the serious risk of cardiac dysfunction,
including systolic arrest. This dose of calcium gluconate
will typically increase the serum Ca2 concentration for
only several hours. Therefore, the acute IV administration
of calcium gluconate should be followed by a slower in-
fusion of calcium.
Ten percent calcium gluconate (90mg of elemental cal-
cium per 10 mL) is used. Calcium gluconate is preferred
because it is less likely than calciumchloride to cause tissue
necrosis if extravasated into the contiguous subcutaneous
space. An IV solution containing 1 mg/mL of elemental
calcium is prepared by adding 11 g of calcium gluconate
(equivalent to 990mg elemental calcium) to normal saline
or 5% dextrose water to provide a final volume of 1000
mL. The calcium should be diluted in dextrose and water
or saline because concentrated calcium solutions are irri-
tating to veins. The IV solution should not contain bicar-
bonate or phosphate, either one of which can form insol-
uble calcium salts. The solution is administered at an
initial infusion rate of 50–100 mL/hr (equivalent to 50
–100 mg/hr). The dose can be adjusted to maintain the
corrected serum calcium concentration at the lower end of
the normal range. A typical infusion rate is 0.5 to 1.5
mg/kg of elemental calcium per hour. Over 8–10 hours,
this infusion protocol will deliver as much as 15 mg/kg
body weight, raising the serum calcium levels by approx-
imately 2 mg/dL (0.5 mmol/l). The electrocardiogram
(ECG) can bemonitored if it is warranted by the situation,
such as in the setting of digoxin therapy.
Active vitamin D metabolites can be additionally ad-
ministered. Because PTH is an important facilitator of the
renal conversion of 25-hydroxyvitmain D to 1,25-dihy-
droxyvitamin D (calcitriol), this active form of vitamin D
is preferred for treatment of patients with hypoparathy-
roidism.The initial doseof calcitriol is typically0.25 to0.5
g twice daily. Its rapid onset of action (hours) and bio-
logic half-life of 4–6 hours make it a useful adjunct in the
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management of acute hypocalcemia. Moreover, the cal-
cemic response to calcitriol can persist for more than 24
hours after a single oral dose (25).
In patients who present with symptomatic hypocalce-
mia requiring urgent IV calcium replacement therapy, the
possible coexistence of hypomagnesemia should always
be considered. This is particularly true in patients who are
not known to have hypoparathyroidism. Their acute hy-
pocalcemia could be explained by the reversible hypo-
parathyroidism of hypomagnesemia. In this setting para-
thyroid hormone secretion is blocked as is the activation
of vitaminD. In addition, there is a reversible resistance to
PTH that is evident when magnesium is administered and
circulating PTH rapidly rises. While IV calcium is a key
element of acute therapy, the hypocalcemia will be diffi-
cult to correct without first normalizing the serum mag-
nesium concentration. If the serum magnesium concen-
tration is low, 2 g (16 mEq) of magnesium sulfate should
be infused as a 10% solution over 10 to 20 minutes, fol-
lowed by 1 g (8 mEq) in 100 mL of infusate per hour. If
magnesium administration is too rapid, excessive urinary
losses of both magnesium and calcium can ensue. The IV
route is generally preferred, even though90%is clearedby
the kidney in the setting of normal renal function. Mag-
nesium can be administered by the intramuscular (IM)
route if necessary, but is generally avoided because of the
relatively high volume that is required to inject, pain, and
“sterile” abscesses that can form. Of note, if a hypopara-
thyroid patient is acutely symptomatic in the setting of
hypocalcemiaandhypomagnesemia (eg,with seizures), IV
calciumshouldbeadministeredacutelyprior toparenteral
administration of magnesium.
The serum calcium level should bemeasured frequently
in the acute setting.The recurrenceof symptoms causedby
hypocalcemia may indicate the need to increase the infu-
sion rate and should be correlated with a simultaneous
serum calcium value to assess the progress of treatment.
Intravenous calcium should be continued until the patient
is receiving an effective regimen of oral calcium and vita-
min D. Intravenous infusions are generally tapered slowly
(over a period of 24 to 48 hours or longer) while oral
therapy is adjusted. Oral calcium and parent vitamin D
therapy, in addition to calcitriol, should be initiated as
soon as is practical.
There are limited data on the use of parathyroid hor-
mone in human subjects who are acutely hypocalcemic. A
few cases have been reported in patients in the postoper-
ative period status post parathyroidectomy, thyroidec-
tomy and renal transplant, and one hypoparathyroid in-
dividual with hypocalcemic cardiomyopathy (26–29).
There is a single case report describing the use of PTH in
acuteneonatal hypocalcemia (30).Thereareno systematic
data available on the use of PTH (1–34) or PTH (1–84) in
themore common setting of acute hypocalcemia against a
backdrop of chronic hypoparathyroidism.
In summary, because a normal level of ionized calcium
is critical for many vital cellular functions, acute hypocal-
cemia in patients with hypoparathyroidism can be a life-
threatening emergency. Urgent management should be
guided by the level of serum calcium, and most impor-
tantly, by the nature and severity of the symptoms. With
the administration of IV calcium therapy, serum calcium
levels can be safely increased and patients typically expe-
rience immediate and substantial relief of symptoms.
Conventional therapy of hypoparathyroidism
Standard therapy of hypoparathyroidism is oral cal-
ciumandvitaminDsupplementation (bothactive andpar-
ent forms) at varying doses, based on clinical judgment.
The goals of therapy are to a) ameliorate symptoms of
hypocalcemia; b) maintain fasting serum calcium within
or slightly below to the low-normal range; c) maintain
fasting serumphosphoruswithin the high normal range or
only slightly elevated;d) avoidorminimizehypercalciuria;
e) maintain a calcium-phosphate product at levels well
below the upper limit of normal (55 mg2/dL2 or 4.4
mmol2/L2); and f) avoid ectopic calcification of the kidney
(stones and nephrocalcinosis) and other soft tissues. Se-
rumcalcium (corrected for albumin), phosphorus and cre-
atinine concentrations should be measured weekly to
monthly during dose adjustments, and twice annually
once a stable regimen has been reached. Urinary calcium
and creatinine should be considered during dose adjust-
ments and should be measured twice annually on a stable
regimen to evaluate for renal toxicity (21, 22).
Calcium
Calcium carbonate and calcium citrate are the most
common forms of oral calcium supplementation. Calcium
carbonate contains 40% elemental calcium and calcium
citrate contains 21% elemental calcium. Calcium carbon-
ate typically requires fewer pills per day and is less expen-
sive and therefore more cost-effective (31). Absorption of
calciumcarbonate is best if takenwithmeals andwith acid
present in the stomach, while calcium citrate is well ab-
sorbed without regard to meals and does not require gas-
tric acid (32). Calcium citrate, therefore, may be more
effective in patientswith achlorhydria or in the presence of
proton pump inhibitors. Illustrating this point, there are
case reports of hypoparathyroid patients presenting with
tetany after initiating therapy with proton pump inhibi-
tors (33–35). Calcium citrate may also be preferred over
calcium carbonate in those who complain of worsening
constipation. Certain “natural” forms of calcium such as
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dolomitemay contain significant amounts of lead or other
heavy metals and are not recommended (36, 37). Coral
calcium, while touted for unsubstantiated health benefits,
is essentially an expensive source of calcium carbonate
(38). Calcium glubionate, gluconate and lactate contain
lower amounts of elemental calcium (6.6%,9%and13%,
respectively) and are generally not used for chronic sup-
plemental calcium therapy. The amorphous polymorphof
calcium carbonate was recently stabilized and the results
of a phase I trial in healthy postmenopausal women
showed increased fractional calcium absorption com-
pared to crystallized calcium carbonate (39). Results of
phase I and II trials in hypoparathyroid subjects have not
yet been published. The amount of elemental calcium sup-
plementation required by patients with hypoparathyroid-
ismvaries greatly, typically 500–1000mg2–3 times daily,
although more frequent dosing may be necessary.
Vitamin D metabolites
Active vitaminD (1,25-dihydroxyvitaminD; calcitriol)
stimulates intestinal calcium transport and absorption
andpromotes bone remodeling (40). SincePTHstimulates
the renal 1-hydroxylation of 25-hydroxyvitamin D, its
absence, as in hypoparathyroidism, is associated with im-
paired activation of vitamin D. Thus, along with calcium,
supplemental active vitamin D is integral to the chronic
management of hypoparathyroidism. Peak serum concen-
trations of calcitriol are reached within 3 to 6 hours of
administration and the increase in serum calcium concen-
tration typically follows 1–3 days later. The elimination
half-life is 5–8hours inadults. Inhypoparathyroidism, the
typical dose for calcitriol is 0.25 to 2 g daily which in-
cludes the normal daily production rate of calcitriol (10,
41–44), although higher levels are sometimes necessary.
When amounts greater than 0.75 g are required, cal-
citriol is typically administered in divided doses.Measure-
ment of 1,25-dihydroxyvitaminDcanbe employed in spe-
cial situations where compliance and/or absorptionmight
be a concern and parenteral administration of calcitriol is
considered.
1-hydroxyvitamin D (alfacalcidol) and dihydrot-
achysterol are vitamin D analogues in use for hypopara-
thyroidism outside the United States. They are rapidly ac-
tivated by the liver to 1,25-dihydroxyvitamin D3 and 25-
hydroxydihydrotachysterol, respectively. The time to
onset of action of alfacalcidol is similar to calcitriol at 1–3
days, with a longer offset of 5–7 days (41, 43, 45, 46). The
time to onset of action of dihydrotachysterol is 4–7 days,
with a time to offset of action of 7–21 days (47, 48). The
typical dose for alfacalcidol is 0.5–3.0 g daily and for
dihydrotachysterol 0.2–1.0 mg daily. Dihydrotachysterol
is used less often now due to the development of the more
specific vitamin D analogues. While toxicity with cal-
citriol is easily managed due to the short half-life, severe
hypercalcemia complicated by renal failure has been de-
scribed with dihydrotachysterol therapy (48).
Patients are also typically supplemented with parent
vitamin D [vitamin D2 (ergocalciferol) or vitamin D3
(cholecalciferol)]. Vitamin D3 may be more potent than
D2, although this has not been firmly established (49, 50).
The half-life of the parent vitamin is 2 to 3 weeks, which
some experts feel can help provide smoother control given
the short half-life of calcitriol. There is also the possibility
that providing the parent vitamin D compound may lead
to heretofore unidentified vitamin D analogues that are
beneficial with regard to “off target” effects. 25-hy-
droxyvitamin D might be able in high concentrations to
occupy vitamin D receptors and thereby have activity.
Nonrenal expression of 1-hydroxylase, not regulated by
PTH, is another potential source of 1,25-dihydroxyvita-
min D (40).
Hypercalcemia is of particular concern in individuals
treated with large doses of parent vitamin D (ergo- or
cholecalciferol) which can accumulate in large amounts in
fat stores and, when released, can result in prolonged hy-
percalcemia (51). In settings where calcitriol is not readily
available and/or is too expensive, parent vitamin D can be
used with due regard to the cautionary note regarding
vitamin D toxicity. We recommend maintaining serum
levels of 25-hydroxyvitaminD towithin thenormal range.
In this disorder, as in othermetabolic bone diseases, levels
of 30 ng/mL (80 nmol/L) are desirable (52).
Adjunctive treatments
Thiazide diuretic therapy can be used to increase distal
renal tubular calciumreabsorption, usually in conjunction
with a low-salt diet to promote calcium retention. Effects
on calcium excretion can be noted within 3 to 4 days of
starting treatment (53, 54). The dose of hydrochlorothi-
azide is 25 to 100 mg daily. Due to the short plasma half-
life of hydrochlorothiazide, twice daily dosing is most of-
ten needed (ie, 25–50 mg twice daily). Chlorthalidone is
another thiazide diuretic that can be used. Doses at the
higher end of the range are usually necessary to signifi-
cantly lower urinary calcium with thiazide therapy, but
these higher doses can be associated with hypokalemia,
hypomagnesemia and hyponatremia. Potassium supple-
mentation or a potassium- and magnesium-sparing di-
uretic (eg, amiloride 2.5 to 5 mg twice a day) may be used
in conjunction with hydrochlorothiazide to prevent hy-
pokalemia and hypomagnesemia (21). The use of thiazide
diuretics varies among experts with some feeling they are
very helpful while others opining that they are not partic-
ularly helpful. Thiazide diuretics are not advised in con-
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genital hypoparathyroidism due to Autoimmune Polyen-
docrine Syndrome type 1 (APS-1) who have concurrent
Addison’s Disease or in Autosomal Dominant Hypocal-
cemia (ADH). In situations where a diuretic is needed for
other reasons, such as congestive heart disease, a thiazide
diuretic shouldbe considered, and loopdiuretics shouldbe
avoided.
Phosphate binders or low-phosphate diets are generally
not used unless hyperphosphatemia is particularly trou-
blesome (22). Patients with activating calcium sensor re-
ceptormutationsmay require substantialmagnesium sup-
plementation due to urinary magnesium losses (55). A
small study in hypoparathyroid subjects demonstrated
that magnesium supplementation does not alter plasma
calcium concentrations in individuals with normal serum
magnesium (56).
Clinical aspects of chronic management
Treatment goals for patients with chronic hypopara-
thyroidism are noted in the previous section (21). One of
the keys to management is to individualize therapy with
particular reference to the serum calcium level. The gen-
erally accepted target serum calcium concentration for
these patients is in the low-normal range, a state in which
symptoms of hypocalcemia are generally uncommon.
Higher serum levels of calcium, even within the normal
range, are to be avoided, because they can increase the risk
of complications. In addition, in some patients, enhanced
sensitivity to the serum calcium concentrationmay lead to
symptoms of hypercalcemia even though serum calcium is
only in the high-normal range. Conversely, some patients
whose serum calcium is in the low normal range may ex-
perience symptoms of hypocalcemia. Individualizedman-
agement, therefore, is necessary to optimize patient care.
Patients with hypoparathyroidism are at risk of many
complications, both from the disease itself as well from
adverse effects of conventional treatment regimens with
oral calcium and active vitamin D (57–59). It is not pos-
sible todeterminewith certaintywhether someof the com-
plications of hypoparathyroidism such as ectopic calcifi-
cations and kidney stones are due to the disease, to
treatment with calcium and vitamin D, often requiring
very high doses, or both.
There arenodata fromclinical trials that gives guidance
to the optimal follow-up intervals or the optimal fre-
quency of laboratory and imaging tests. As a result, guide-
lines for the management of the disease have only recently
been offered (60, 61). This section deals only with the use
of conventional approaches tomanagement.Replacement
therapy with rhPTH (1–84) is covered in the next section.
The frequency with which biochemical parameters (se-
rum calcium, potassium, magnesium, phosphate, albu-
min, creatinine) should be monitored varies with the suc-
cess of controlling those biochemical parameters. In very
well controlled patients, yearly or semiannual measure-
ments might be sufficient. More often, though, more fre-
quent monitoring is needed such as every 3 or 6 months.
24-hour urinary calcium and creatinine excretion should
be measured at least once yearly because hypercalciuria is
a common concern in this disease. Some experts also rec-
ommend urinary magnesiummeasurement. There are sit-
uations in which more frequent measurement of urinary
calcium and amore complete urinary profile for stone risk
factors may be needed. At the initial evaluation, baseline
imaging of the kidneys with ultrasound or computed to-
mography (CT) is recommended (62). Surveillance for the
appearance of nephrolithiasis or nephrocalcinosismay re-
quire repeat ultrasound or other imagingmodality every 5
years or earlier if signs or symptoms of kidney stones de-
velop. Central nervous system calcifications, especially in
the basal ganglia, are a well-known complication of hy-
poparathyroidism (57, 63). However, the clinical signifi-
cance of these calcifications is unclear. In patients with
long-standing hypoparathyroidism, imaging of the brain
for basal ganglia and other sites of ectopic calcification is
reasonable.
Patients suffering from hypoparathyroidism are at risk
for cataracts (64). While the standard senile cataract is
characterized by nuclear opacities, cataracts associated
with hypoparathyroidism show predominantly cortical
involvement. Slit-lamp and ophthalmoscopic examina-
tions are recommended in all patients who develop symp-
toms such as blurred vision or sensitivity to light. Surgical
treatment of cataracts is typically a decision made by the
ophthalmologist.
Childrenwith hypoparathyroidism can have awide va-
riety of dental manifestations and abnormalities such as
hypoplastic teeth that might require special care.
In adults with hypoparathyroidism, bone microarchi-
tecture is abnormal and bone mineral density (BMD) as
measured by dual-energy x-ray absorptiometry (DXA) is
often above age- and sex-matched controls (22). The clin-
ical significance of these abnormalities is unclear. Guide-
lines for when repeat measurements should be made
should follow recommendations of the International So-
ciety of Clinical Densitometry (65).
A key aspect of ongoing follow-up is engaging the pa-
tient as a partner in his or her medical care. Patient orga-
nizations that have formed in many countries, as well as
rare disease organizations, offer a variety of resources for
patients and their families, as well as health care providers
(66–69). It is highly desirable for patients with hypopara-
thyroidism to have a basic understanding of the underly-
ing pathophysiology, the rationale for treatment, and
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signs and symptoms indicative of complications of the dis-
order. This is particularly important due to the fact that
hypoparathyroidism is a rare disorder, and medical pro-
viders may not be familiar with the potential manifesta-
tions of the disease. In addition, the patient who under-
stands the importance of preventing kidneydamagedue to
excessive urinary calcium excretionmight bemore accept-
ing of the 24-hour urine collections, as well as other mon-
itoring approaches that might otherwise be seen as an in-
convenience. Ongoing care with a provider familiar with
the treatment of this disorder is critical for meeting the
complex needs of patients and to optimize their outcomes.
Replacement therapy of hypoparathyroidism with
PTH peptides
Hypoparathyroidism is typically managed with cal-
cium, active vitamin D, and, at times, thiazide diuretics.
With sufficient expertise the serum calcium can be main-
tained, although often requiring the use of very high doses
of calcium and active vitamin D. Some individuals, how-
ever, despite valiant efforts continue to be difficult to con-
trol on conventional therapy, even when high doses are
employed. Moreover, there are concerns with prolonged
use of calcium and active vitamin D in large doses, par-
ticularly with regard to hypercalciuria, nephrolithiasis,
nephrocalcinosis and ectopic soft tissue calcification (22).
In addition, conventional therapywith calcium and active
vitamin D does not alleviate quality of life (QOL) com-
plaints (64, 70, 71) nor does it reverse abnormalities in
bone remodeling characteristic of the disease (72). In
short, conventional therapy does not provide a physiolog-
ical replacement remedy for the lack of PTH in
hypoparathyroidism.
Until recently, hypoparathyroidism was the last re-
maining classic endocrine deficiency disease for which the
missing hormone was not an approved therapy. Over the
past twodecades, studies of teriparatide [PTH (1–34)] and
the full-length natural secretory product of the parathy-
roid glands, PTH (1–84), have ushered a new era in the
management of this disease. In January, 2015, the FDA
approved the use of recombinant human (rh) PTH (1–84)
for the management of hypoparathyroidism (73).
Use of PTH (1–34) in hypoparathyroidism
In a series of classic studies,Winer et al evaluated vary-
ing dose regimens of the biologically active amino-termi-
nal fragment, PTH (1–34), including once-daily and
twice-daily injections in adults and children of all etiolo-
gies. Early studies showed PTH (1–34) achieved superior
results by maintaining normal serum calcium and urinary
calcium excretion levels when compared to conventional
therapy (74). Patients who received PTH (1–34) did not
concurrently receive calcitriol supplements. Thiazides and
phosphate binders were not used in any of the studies. A
28-week study by the same group comparing daily with
twice daily injections showed twice-daily dosing with
PTH (1–34) produced significantly higher serum calcium
levels with less fluctuation throughout the day while si-
multaneously normalizing urine calcium levels in patients
of all etiologies except those with a calcium receptor mu-
tation (74). A longer 3-year study by Winer et al showed
PTH (1–34) superior to active vitamin D by maintaining
urinary calcium excretion in the normal range along with
stable bone density Z-scores in adults and children (75).
Children receiving PTH (1–34) over three years had stable
renal function, normal linear growth and bone accrual
(76).
To further refine replacement therapy with PTH (1–
34), Winer recently utilized a pump delivery system and
compared it with twice daily injections (77, 78). In this
6-month study, pump delivery produced normal, steady
state calcium levels with minimal fluctuation and avoided
the rise in serum and urine calcium levels that are evident
soon after PTH (1–34) injection. Themarked reduction in
urinary calcium excretion when PTH (1–34) is adminis-
tered by pumpwould appear to emphasize a physiological
point that PTHhas tobe continuously exposed to the renal
tubule in order for the renal calcium-conserving effects to
be realized. Pump delivery of PTH (1–34) achieved simul-
taneous normalization of markers of bone turnover, se-
rum calcium, and urine calcium excretion. These results
were achieved with a smaller daily PTH (1–34) dose and
a reduced need for magnesium supplementation com-
pared with the twice daily PTH (1–34) injection regimen.
Use of rh PTH (1–84) in hypoparathyroidism
The rationale for using rhPTH (1–84) for hypopara-
thyroidism is that, in contrast to PTH (1–34), it is the
native hormone and, thus, would replace what is truly
missing in this disease. For reasons that have not been fully
elucidated, the effective half-life of PTH (1–84) is longer
thanPTH(1–34) resulting inprotocols that havebeenable
to utilize effectively once daily dosing (25, 75, 76). Initial
studies demonstrated proof of concept with daily or every
other day dosing by showing maintenance of serum cal-
ciumwhile significantly reducing the need for oral calcium
and vitamin D (77, 78).
Sikjaer et al (78) studied 62 patientswhowere random-
ized in a double-blind protocol comparing a fixed dose of
rhPTH (1–84) 100g daily or placebo for 6months.Over
this rather short period of time, the need for active vitamin
D and calcium supplements to maintain normal calcium
levels fell significantly by 50% and 11%, respectively, in
the group that received drug. Following a time course in
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which serum calciumwas monitored after injection, 71%
of patients treated with rhPTH (1–84) developed hyper-
calcemia at one or more measurements during a 24-hour
period (76). rhPTH (1–84) reduced urinary calcium ex-
cretion 2–8 hours after injection but over the 24-hour
period, urinary calcium excretion did not change (76).
Similarly, urinaryphosphate excretion increasedonlydur-
ing the first 8 hours after rhPTH (1–84) injection (76).
In longer studies, rhPTH (1–84) replacement therapy
continued todemonstrate these advantages (79, 80). In the
work of Cusano et al, reductions in oral calcium and vi-
tamin D requirements were significant and maintained
over a 4-year period along with serum calcium levels that
were maintained (79). Reductions in urinary calcium ex-
cretionweremore variable and not constant over time but
did achieve significance at 3 years. Bonemineral density of
the lumbar spine byDXA increased, while hip densitywas
stable and thedistal 1/3 radius site fell. Theworkof Sikjaer
et al showed small but significant declines at the spine and
hip, but not the 1/3 radius, by DXA.However, in contrast
to areal BMD measurements by DXA, trabecular volu-
metric BMD as assessed by quantitative CT (QCT) scans
at the lumbar spine actually increased significantly in re-
sponse to therapy.
Newer imaging modalities are being assessed to deter-
mine other aspects of rhPTH (1–84) therapy in hypopara-
thyroidism. Trabecular Bone Score (TBS), a textural anal-
ysis of the lumbar spineDXA image, shows values that are
within the normal range in patients who have not been
treated with PTH. After rhPTH (1–84) for up to 4 years,
TBS values increase in both premenopausal and post-
menopausal women. By QCT, Sikjaer et al (81) have
shown that the cortical, but not the trabecular, compart-
ment of the hip, is reduced with rhPTH (1–84) therapy.
Bone turnover markers increase quickly and markedly
with the administration of rhPTH (1–84). Both bone for-
mation and bone resorption markers reach a peak within
approximately a year and then decline to levels that rep-
resent a new baseline that is higher than pretreatment
baseline values. These results are confirmed at the tissue
level byhistomorphometric analysis of bonebiopsies from
patients with hypoparathyroidism. As shown by Rubin et
al, transiliac crest bone biopsies using a quadruple label
technique demonstrate a marked increase in tetracycline-
labeled surfaces, representing bone formation, within 3
months of rhPTH (1–84) administration (82). By more
standard conventional bone biopsy techniques, marked
changes in both trabecular and cortical compartments are
seen. Within a year, trabecular width is reduced and tra-
becular number is increased. In the work of Sikjaer et al,
intratrabecular tunneling could be demonstrated in ap-
proximately half of the biopsied subjects treated with
rhPTH (1–84) whereas none of the placebo treated pa-
tients showed signs of intratrabecular tunneling (81).
In addition to these biochemical and densitometric
changes with the administration of rhPTH (1–84) in hy-
poparathyroidism, changes inQOL(QoL)metrics arealso
noteworthy. In the short-term study of Sikjaer et al, QoL
as assessed by the 36-item Short FormHealth Survey (SF-
36)was significantly reduced in hypoparathyroid patients
compared with norm-based scores. Compared with pla-
cebo, rhPTH (1–84) did not improveQoL (71). Thework
of Cusano et al also confirmed the reduction in QoLmea-
sures in hypoparathyroid subjects by the SF-36 scale. In
contrast to the work of Sikjaer et al, however, the work of
Cusano et al which extended over a longer period of time
demonstrated a significant increase in virtually all 8 QOL
measures at 1 year (70). These improvements were sus-
tained over a period of 5 years (80).
Phase III study of rhPTH (1–84) in
hypoparathyroidism
The pivotal phase III trial of rhPTH (1–84) in hypo-
parathyroidism was reported by Mannstadt et al (83).
This multicenter, multinational, placebo-controlled, dou-
ble blinded trial compared rhPTH (1–84) administered
with a titration algorithm (50 g could be increased to 75
g or to 100 g). The trial’s triple primary end point was
a) reduction of calcium supplementation by 50%ormore;
b) reduction of active vitaminD supplementation by 50%
or more; 3) maintenance of a stable serum calcium levels
within the normal range. The results of the study showed
that 53% of study subjects receiving rhPTH (1–84) met
this triple primary end point, while only 2% of study sub-
jects receiving placebo did so (P  .001). The secondary
endpoint, the proportion of subjects who were able to
eliminate all active vitamin D supplemtnation while re-
ducing the dose of oral calcium to no more than 500 mg
per day was also highly significant in favor of the study
subjects who received rhPTH (1–84): 43% vs. 5% (P 
.001). In most study subjects (52%), rhPTH (1–84) was
titrated up to a dose of 100 g/d. Adverse events were
similar with the most common reports related to signs of
hypocalcemia, namely, muscle spasms, paresthesias,
headache and nausea.
Two other studies with rhPTH (1–84) have been re-
ported recently. RELAY is a short, 8 week, double-
blinded, multinational, randomized trial that tested
whether doses as low as 25 g per daily could be effica-
cious in hypoparathyroidism (84, 85). Although some
study subjects were able to meet the primary end point
(oral calcium not more than 500 mg/d and active vitamin
D not more than 0.25 g/d) most patients did not, con-
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firming the results of theREPLACEtrial thatmostpatients
require amount of rhPTH (1–84) more than 50 g/d.
Theother studyof recent note is calledRACE.This trial
is an open-label, extension of the REPLACE and RELAY
trials conducted in the United States only (84–86). The
initial results at 1 year provide confirmatory evidence of
the primary end points of the REPLACE trial, carried out
for 1 year.
Management guidelines
With the recent approval of rhPTH (1–84) by the U.S.
Food and Drug Administration (FDA), replacement ther-
apy is now available and is expected to contribute to im-
provedmanagementofhypoparathyroidism.Approvedas
an adjunct to calcium and vitamin D, rhPTH (1–84) is
recommended for patients who cannot be well-controlled
on conventional therapy alone. This directive leaves room
for interpretation of what constitutes a well-controlled
individual. The physician should consider the following
questions when assessing whether the patient is or is not
well controlled.
1.Does thepatient’s serumcalciumexhibit large swings
with frequent episodes of significant hypo- and/or
hypercalcemia?
2. Can the serum phosphate and/or calcium-phosphate
product be maintained within acceptable range?
3. Is the risk for renal complications high due to hy-
percalciuria or an unfavorable urinary biochemical stone
risk profile despite optimization of conventional therapy?
4. Does the patient show evidence for renal complica-
tions such as nephrocalcinosis, nephrolithiasis, or chronic
renal kidney disease?
5. Is the amount of oralmedications required to control
symptoms of hypocalcemia excessive?
6. Does the patient have a condition that might render
calcium and vitamin D absorption from the GI tract vari-
able (eg, malabsorption, inflammatory bowel disease, or
celiac disease)?
7. Does the patient have an autosomal dominant form
of hypocalcemia due to an activating mutation in the cal-
cium sensing receptor? These patients are at great risk of
renal damage.
The decision to recommend the use of rhPTH (1–84) in
hypoparathyroidismshouldalso take intoaccount the fact
that it is at this time a very expensive therapy. The points
made above with regard to considering rhPTH (1–84) as
a therapy for hypoparathyroidism, should, therefore, also
bear in mind cost of the product.
An approach to management with rhPTH (1–84)
The official recommendations are stated in the package
insert to initiate rhPTH (1–84) at 50 g once daily as a
subcutaneous injection into the thigh and to concomi-
tantly decrease the dose of active vitamin D by 50%. Se-
rum calcium (and albumin) concentrations are to bemon-
itored every 3–7 days after initiation of therapy and after
each dose change. The dose of rhPTH (1–84) is to be
titrated every four weeks with the goal to discontinue ac-
tive vitamin D and to reduce oral calcium supplements to
an amount as low as 500 mg per day while keeping serum
calciumwithin the low-normal range. As an alternative to
the recommended reduction of active vitamin D first (as
was done in the REPLACE trial), reducing oral calcium
first (also by 50%), especially if the calcium supplement
use is high, should also be possible. The final dosage re-
quirement of rhPTH (1–84) required for each patient to
achieve optimized management cannot be predicted by
parameters such asweight or previous amounts of calcium
and active vitaminDvia conventional treatment. After the
initial titration phase when a stable regimen is achieved,
serum calcium and phosphate should be monitored every
3–6months and urinary calcium excretion at least yearly.
It is possible that some patients who have been started
on rhPTH (1–84) will be advised or, on their own, decide
to stop therapy. Prior to discontinuing rhPTH (1–84),
serum 25-hydroxyvitamin D levels should be in the nor-
mal range. For patients receiving rhPTH (1–84) alone
without any calciumand vitaminDanalogs, a brief period
of therapy with concomitant rhPTH (1–84), calcitriol, er-
go- or cholecalciferol (parent vitaminD) and calciummay
be necessary to allow the usual 3–4 day onset of conven-
tional therapy to become fully effective. Furthermore, be-
fore discontinuing chronic rhPTH (1–84) therapy, one
should considerpotential factors thatmay lead toaheight-
ened risk for suddenhypocalcemia such asmalabsorption,
illness, and menses in premenopausal women. A recent
case series described acute hypocalcemia in two patients
after the abrupt discontinuation of chronic PTH (1–34)
therapy. To avoid this, subsequent patients received two-
to threefold the baseline requirements of standard therapy
during their transition from PTH (1–34) (87).
Safety
Similar to rhPTH (1–34) for the treatment of osteopo-
rosis, rhPTH (1–84) was approved by the FDA with a
‘black box’ warning due to the evidence that both PTH
molecules cause osteosarcoma in rats (88, 89). Approval
of teriparatide for osteoporosis is limited to 2 years at a 20
g daily dose but no limit has been imposed on the dura-
tion of rhPTH (1–84) therapy for hypoparathyroidism.
With extensive clinical human experience with PTH (1–
34) since its approval 13years agoandwith rhPTH(1–84)
for a shorter period of time, no signals with either peptide
have emerged to suggest that human subjects treated with
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either form of PTH are at increased risk for the develop-
ment of osteosarcoma (90–92). Only a handful of cases of
osteosarcoma have appeared in human subjects exposed
to teriparatide, a number that is below what would be
expected on the basis of epidemiological considerations of
the background incidence of osteosarcoma in human sub-
jects (92). In the ongoing surveillance registry of osteo-
sarcoma, there is no evidence that any subject with osteo-
sarcoma had ever been exposed to teriparatide (91).
Hypercalcemia is another safety issue but this concern can
be mitigated by careful patient monitoring and titration
protocols for calcium, active vitaminDand rhPTH(1–84)
(73). In the experience ofCusano et al (79), hypercalcemia
was seen only rarely.
rhPTH (1–84) is available to patients with hypopara-
thyroidism only through a registry known as Risk Evalu-
ation and Mitigation Strategies (REMS). Physicians who
intend to prescribe rhPTH (1–84) must be registered in
this system.
Summary
Over the past 2 decades, patients treated with PTH
(1–34) or rhPTH (1–84) for hypoparathyroidism have
shown improved calcium homeostasis. The recent FDA
approval of rhPTH (1–84) represents an important ad-
vance in the management of hypoparathyroidism. It pro-
vides the natural hormone that these subjects are lacking
andpermitsmajor reductions in the need for supplemental
calcium and active vitamin D while maintaining normal
calcium levels. Evidence also suggests that QOL is im-
proved. Questions remain regarding ideal dosing and ad-
ministration regimens for rhPTH (1–84) and its long-term
effects on calcium homeostasis, bone, kidney and other
organs.
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